Cargando…
A nanoparticle vaccine displaying the ookinete PSOP25 antigen elicits transmission-blocking antibody response against Plasmodium berghei
BACKGROUND: Safe and effective vaccines are crucial for the control and eventual elimination of malaria. Novel approaches to optimize and improve vaccine efficacy are urgently required. Nanoparticle-based delivery platforms are considered potent and powerful tools for vaccine development. METHODS: I...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10626823/ https://www.ncbi.nlm.nih.gov/pubmed/37932796 http://dx.doi.org/10.1186/s13071-023-06020-8 |
_version_ | 1785131420213051392 |
---|---|
author | Yao, Guixiang Min, Hui Yu, Xinxin Liu, Fei Cui, Liwang Cao, Yaming |
author_facet | Yao, Guixiang Min, Hui Yu, Xinxin Liu, Fei Cui, Liwang Cao, Yaming |
author_sort | Yao, Guixiang |
collection | PubMed |
description | BACKGROUND: Safe and effective vaccines are crucial for the control and eventual elimination of malaria. Novel approaches to optimize and improve vaccine efficacy are urgently required. Nanoparticle-based delivery platforms are considered potent and powerful tools for vaccine development. METHODS: In this study, we developed a transmission-blocking vaccine against malaria by conjugating the ookinete surface antigen PSOP25 to the Acinetobacter phage coat protein AP205, forming virus-like particles (VLPs) using the SpyTag/SpyCatcher adaptor system. The combination of AP205-2*SpyTag with PSOP25-SpyCatcher resulted in the formation of AP205-PSOP25 complexes (VLP-PSOP25). The antibody titers and avidity of serum from each immunization group were assessed by ELISA. Western blot and IFA were performed to confirm the specific reactivity of the elicit antisera to the native PSOP25 in Plasmodium berghei ookinetes. Both in vitro and in vivo assays were conducted to evaluate the transmission-blocking activity of VLP-PSOP25 vaccine. RESULTS: Immunization of mice with VLP-PSOP25 could induced higher levels of high-affinity antibodies than the recombinant PSOP25 (rPSOP25) alone or mixtures of untagged AP205 and rPSOP25 but was comparable to rPSOP25 formulated with alum. Additionally, the VLP-PSOP25 vaccine enhanced Th1-type immune response with remarkably increased levels of IgG2a subclass. The antiserum generated by VLP-PSOP25 specifically recognizes the native PSOP25 antigen in P. berghei ookinetes. Importantly, antisera generated by inoculation with the VLP-PSOP25 could inhibit ookinete development in vitro and reduce the prevalence of infected mosquitoes or oocyst intensity in direct mosquito feeding assays. CONCLUSIONS: Antisera elicited by immunization with the VLP-PSOP25 vaccine confer moderate transmission-reducing activity and transmission-blocking activity. Our results support the utilization of the AP205-SpyTag/SpyCatcher platform for next-generation TBVs development. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13071-023-06020-8. |
format | Online Article Text |
id | pubmed-10626823 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-106268232023-11-07 A nanoparticle vaccine displaying the ookinete PSOP25 antigen elicits transmission-blocking antibody response against Plasmodium berghei Yao, Guixiang Min, Hui Yu, Xinxin Liu, Fei Cui, Liwang Cao, Yaming Parasit Vectors Research BACKGROUND: Safe and effective vaccines are crucial for the control and eventual elimination of malaria. Novel approaches to optimize and improve vaccine efficacy are urgently required. Nanoparticle-based delivery platforms are considered potent and powerful tools for vaccine development. METHODS: In this study, we developed a transmission-blocking vaccine against malaria by conjugating the ookinete surface antigen PSOP25 to the Acinetobacter phage coat protein AP205, forming virus-like particles (VLPs) using the SpyTag/SpyCatcher adaptor system. The combination of AP205-2*SpyTag with PSOP25-SpyCatcher resulted in the formation of AP205-PSOP25 complexes (VLP-PSOP25). The antibody titers and avidity of serum from each immunization group were assessed by ELISA. Western blot and IFA were performed to confirm the specific reactivity of the elicit antisera to the native PSOP25 in Plasmodium berghei ookinetes. Both in vitro and in vivo assays were conducted to evaluate the transmission-blocking activity of VLP-PSOP25 vaccine. RESULTS: Immunization of mice with VLP-PSOP25 could induced higher levels of high-affinity antibodies than the recombinant PSOP25 (rPSOP25) alone or mixtures of untagged AP205 and rPSOP25 but was comparable to rPSOP25 formulated with alum. Additionally, the VLP-PSOP25 vaccine enhanced Th1-type immune response with remarkably increased levels of IgG2a subclass. The antiserum generated by VLP-PSOP25 specifically recognizes the native PSOP25 antigen in P. berghei ookinetes. Importantly, antisera generated by inoculation with the VLP-PSOP25 could inhibit ookinete development in vitro and reduce the prevalence of infected mosquitoes or oocyst intensity in direct mosquito feeding assays. CONCLUSIONS: Antisera elicited by immunization with the VLP-PSOP25 vaccine confer moderate transmission-reducing activity and transmission-blocking activity. Our results support the utilization of the AP205-SpyTag/SpyCatcher platform for next-generation TBVs development. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13071-023-06020-8. BioMed Central 2023-11-06 /pmc/articles/PMC10626823/ /pubmed/37932796 http://dx.doi.org/10.1186/s13071-023-06020-8 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Yao, Guixiang Min, Hui Yu, Xinxin Liu, Fei Cui, Liwang Cao, Yaming A nanoparticle vaccine displaying the ookinete PSOP25 antigen elicits transmission-blocking antibody response against Plasmodium berghei |
title | A nanoparticle vaccine displaying the ookinete PSOP25 antigen elicits transmission-blocking antibody response against Plasmodium berghei |
title_full | A nanoparticle vaccine displaying the ookinete PSOP25 antigen elicits transmission-blocking antibody response against Plasmodium berghei |
title_fullStr | A nanoparticle vaccine displaying the ookinete PSOP25 antigen elicits transmission-blocking antibody response against Plasmodium berghei |
title_full_unstemmed | A nanoparticle vaccine displaying the ookinete PSOP25 antigen elicits transmission-blocking antibody response against Plasmodium berghei |
title_short | A nanoparticle vaccine displaying the ookinete PSOP25 antigen elicits transmission-blocking antibody response against Plasmodium berghei |
title_sort | nanoparticle vaccine displaying the ookinete psop25 antigen elicits transmission-blocking antibody response against plasmodium berghei |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10626823/ https://www.ncbi.nlm.nih.gov/pubmed/37932796 http://dx.doi.org/10.1186/s13071-023-06020-8 |
work_keys_str_mv | AT yaoguixiang ananoparticlevaccinedisplayingtheookinetepsop25antigenelicitstransmissionblockingantibodyresponseagainstplasmodiumberghei AT minhui ananoparticlevaccinedisplayingtheookinetepsop25antigenelicitstransmissionblockingantibodyresponseagainstplasmodiumberghei AT yuxinxin ananoparticlevaccinedisplayingtheookinetepsop25antigenelicitstransmissionblockingantibodyresponseagainstplasmodiumberghei AT liufei ananoparticlevaccinedisplayingtheookinetepsop25antigenelicitstransmissionblockingantibodyresponseagainstplasmodiumberghei AT cuiliwang ananoparticlevaccinedisplayingtheookinetepsop25antigenelicitstransmissionblockingantibodyresponseagainstplasmodiumberghei AT caoyaming ananoparticlevaccinedisplayingtheookinetepsop25antigenelicitstransmissionblockingantibodyresponseagainstplasmodiumberghei AT yaoguixiang nanoparticlevaccinedisplayingtheookinetepsop25antigenelicitstransmissionblockingantibodyresponseagainstplasmodiumberghei AT minhui nanoparticlevaccinedisplayingtheookinetepsop25antigenelicitstransmissionblockingantibodyresponseagainstplasmodiumberghei AT yuxinxin nanoparticlevaccinedisplayingtheookinetepsop25antigenelicitstransmissionblockingantibodyresponseagainstplasmodiumberghei AT liufei nanoparticlevaccinedisplayingtheookinetepsop25antigenelicitstransmissionblockingantibodyresponseagainstplasmodiumberghei AT cuiliwang nanoparticlevaccinedisplayingtheookinetepsop25antigenelicitstransmissionblockingantibodyresponseagainstplasmodiumberghei AT caoyaming nanoparticlevaccinedisplayingtheookinetepsop25antigenelicitstransmissionblockingantibodyresponseagainstplasmodiumberghei |